GAMMA Investing LLC increased its stake in shares of Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) by 1,104.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,605 shares of the biotechnology company's stock after acquiring an additional 71,161 shares during the quarter. GAMMA Investing LLC owned approximately 0.33% of Benitec Biopharma worth $1,010,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also bought and sold shares of BNTC. Suvretta Capital Management LLC boosted its stake in shares of Benitec Biopharma by 1.5% during the fourth quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock valued at $113,165,000 after purchasing an additional 130,956 shares during the period. Franklin Resources Inc. increased its stake in shares of Benitec Biopharma by 269.0% in the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after buying an additional 2,142,643 shares during the period. Janus Henderson Group PLC raised its holdings in Benitec Biopharma by 198.5% during the 4th quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock valued at $33,268,000 after buying an additional 1,739,904 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Benitec Biopharma by 134.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after buying an additional 1,131,129 shares during the last quarter. Finally, Infinitum Asset Management LLC purchased a new stake in Benitec Biopharma during the 4th quarter valued at $2,652,000. 52.19% of the stock is owned by hedge funds and other institutional investors.
Benitec Biopharma Trading Down 3.5%
Benitec Biopharma stock traded down $0.52 during mid-day trading on Friday, reaching $14.42. 39,469 shares of the company traded hands, compared to its average volume of 46,158. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.80 and a quick ratio of 14.80. Benitec Biopharma Limited has a 52-week low of $5.74 and a 52-week high of $17.15. The firm has a market capitalization of $378.53 million, a price-to-earnings ratio of -9.55 and a beta of 0.44. The firm's 50 day moving average price is $14.38 and its 200 day moving average price is $12.81.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.12. On average, analysts anticipate that Benitec Biopharma Limited will post -1.48 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. JMP Securities reissued a "market outperform" rating and issued a $20.00 price target on shares of Benitec Biopharma in a report on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and set a $28.00 target price on shares of Benitec Biopharma in a report on Monday, May 19th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $23.83.
Get Our Latest Stock Analysis on Benitec Biopharma
Insider Buying and Selling at Benitec Biopharma
In other news, Director Suvretta Capital Management, L acquired 900,000 shares of the stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $13.00 per share, with a total value of $11,700,000.00. Following the completion of the transaction, the director now owns 8,793,245 shares of the company's stock, valued at $114,312,185. This represents a 11.40% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.30% of the company's stock.
Benitec Biopharma Profile
(
Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Further Reading
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
